Goal of the Project Generate a data package that will support the advancement of a molecule derived from the current lead series of Super Elongation Complex Disruptors (SEC-KL) into an oncology clinical study by April 15, 2023, or a suitable alternate molecule or back-up (SEC-BU) by April 15, 2024 and/or the licensing of the intellectual property associated with this collaboration project to a third party by April 15, 2024. Target Product Profile The project aims to develop a medicinal therapy that will: • Disrupt oncogenic transcriptional programming • Reduce/eliminate tumor cell proliferation • Improve survival outcome for patients
|Effective start/end date||4/15/19 → 4/14/24|
- Lakeside Discovery, LLC (Agmt 5/18/18)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.